Measuring health-related quality of life in drug clinical trials: Is it given due importance?

Pharmacy World and Science

Volumn 30, Issue 2, 2008, Pages 154-160

  Miguel, Ramón San ^a   López González, Ana María ^b   Sanchez Iriso, Eduardo ^c   Mar, Javier ^d   Cabasés, Juan M ^c  

^a HOSPITAL SANTA BÁRBARA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

^d Hospital Alto Deba   (Spain)

Author keywords

Clinical trial; Health related quality of life; Pharmacoeconomics; Quality of life

Indexed keywords

CLINICAL EVALUATION; CLINICAL STUDY; DAILY LIFE ACTIVITY; DRUG RESEARCH; HEALTH STATUS; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; ECONOMICS, PHARMACEUTICAL; HEALTH STATUS; HUMANS; PERSONALITY INVENTORY; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 39749122034     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9152-9     Document Type: Review

References (70)

1. Talbot LA, Morrell CH, Metter EJ, Fleg JL. Comparison of cardiorespiratory fitness versus leisure time physical activity as predictors of coronary events in men aged 65 years. Am J Cardiol 2002;89:1187-92.
2. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-52.
3. Testa MA, Simonson DC. Current concepts: assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-40.
4. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global burden of disease study. Lancet 1997;349:1436-42.
5. Hobart J. Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible? Curr Opin Neurol 2002;15:721-4.
6. Mar J, Rueda JR, Durán-Cantolla J, Schechter C, Chilcott J. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J 2003;21:515-22.
7. Patrick DL. What constitutes quality of life? Concepts and dimens Clin Nutr 1988;7:53-63.
8. Wood RW, Diehr P, Wolcott BW, Slay L, Tompkins RK. Reproducibility of clinical data and decisions in the management of upper respiratory illnesses: a comparison of physicians and non-physician providers. Med Care 1979;17:767-79.
9. Guyatt GH, Veldhuyzen Van Zanten SJ, Feeny DH, Patrick DL. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ 1989;140:1441-8.
10. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): conceptual ramework and item selection. Med Care 1992;30:473-58.
11. EuroQol group. EuroQol - A new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
12. Hunt SM, McEwen J, McKenna SP. Measure health status. London: Croom Helm; 1986.
13. Bergner M, Bobbitt RA, Pollard WE, Marin DP, Gilson BS. The sickness impact profile. Validation of a health status measure. Med Care 1976;14:57-67.
14. Jones PW. St. George's respiratory questionnaire: MCID. COPD 2005;2:75-9.
15. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 1992;45:461-72.
16. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the medical outcomes study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997;6:531-54.
17. Mitchell A, Guyatt G, Singer J, Irvine EJ, Goodacre R, Tompkins C, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988;10:306-10.
18. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md Med J 1965;14:61-5.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The european organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
20. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, The Clinical Significance Consensus Meeting Group. Mayo Clin Proc 2002;77:371-83.
21. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
22. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2004.
23. Pearson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 2005;294:2618-22.
24. Henry DA, Hill SR, Harris A. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme. JAMA 2005;294:2630-2.
25. Sackett DL, Straus SE, Richardson WS, Rosenber W, Haynes RB. Medicina basada en la evidencia [Evidence-Based Medicine]. Hardcourt: Madrid; 2001.
26. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
27. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
28. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-34.
29. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.
30. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72.
31. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N Engl J Med 2005;352:2193-201.
32. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
33. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
34. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352:2499-507.
35. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-86.
36. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
37. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.
38. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
39. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
40. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. N Engl J Med 2005;353:1114-23.
41. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353:2025-33.
42. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42.
43. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71.
44. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations: a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54.
45. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease: a randomised placebo-controlled trial. Lancet 2005;365:1552-60.
46. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people: a randomised placebo-controlled trial. Lancet 2005;365:1621-8.
47. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005;365:2007-13.
48. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial. Lancet 2005;366:921-9.
49. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study. Lancet 2005;366:1527-37.
50. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366:1935-44.
51. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40.
52. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-93.
53. Avenell A, Campbell MK, Cook JA, Hannaford PC, Kilonzo MM, McNeil G, et al. Effect of multivitamin and mineral supplements on morbidity from infections in older people: pragmatic, randomised, double blind, placebo controlled trial. BMJ 2005;331:324-7.
54. 3) for prevention of fractures in primary care. BMJ 2005;330:1003-6.
55. Escobar-Morreale HF, Botella-Carretero JI, Gómez-Bueno M, Galán JM, Barrios V, Sancho J. Thyroid hormona replacement therapy in primary hypothiroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005;142:412-24.
56. Bezjak A, Winton T, Ding K, Graham B, Seymour L Ayoub J, et al. Quality of life in a trail of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer. Lung Cancer 2003;41(suppl 2):S20.
57. Abbott J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes 2005;3:19.
58. Clarke SA, Eiser C. The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004;2:66.
59. Eiser C. Use of quality of life measures in clinical trials. Ambul Pediatr 2004;4(4 Suppl):395-9.
60. Kong SX, Gandhi SK. Methodologic assessments of quality of life measures in clinical trials. Ann Pharmacother 1997;31:830-6.
61. Kim J, Morris CB, Schulman KA. The role of the Food and Drug Administration in pharmacoeconomic evaluation during the drug development process. Drug Inf J 2000;34:1207-13.
62. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006;24:3178-86.
63. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry 2006;67:1397-403.
64. McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics 2006;24:947-52.
65. Vijan S. Should we abandon QALYs as a resource allocation tool?. Pharmacoeconomics 2006;24:953-4.
66. Prescrire Editorial Staff. European and French pharmaceutical market assessed by Prescrire in 2005: mainly bogus innovation. Farm Hosp 2006;30:68-70.
67. Greenberg D, Rosen AB, Olchanski NV, Stone PW, Nadai J, Neumann PJ. Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis. BMJ 2004;328:1536-7.
68. Rivero-Arias O, Campbell H, Gray A, Fairbank J, Frost H, Wilson-MacDonald J. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial. BMJ 2005;330:1239-43.
69. Zhu W. Making bootstrap statistical inferences: a tutorial. Res Q Exerc Sport 1997;68:44-55.
70. Salkeld G,Henry D, Hill S, Lang D, Freemantle N, D'Assuncao J. What drives health-care spending priorities? An international survey of health-care professionals. PLoS Med 2007;4:e94.